Health Care • Medical Specialities
$235.99 ▼ -54.07
(-18.64%)
MKT CAP: $35.63B • VOL: 5.39M
52W L $113 52W H $309
ILMN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-28 | FY 2024
FILED 2024-12-29 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.34B | $4.37B | $4.50B |
| YoY Revenue Growth % | -0.7% | -2.9% | — |
| Gross Profit | $2.87B | $2.86B | — |
| Gross Margin % | 66.1% | 65.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $807.0M | -$833.0M | -$1.07B |
| Operating Margin % | 18.6% | -19.1% | -23.7% |
| Net Income (GAAP) | $850.0M | -$1.22B | -$1.16B |
| EBITDA (Normalized) | $925.4M | -$730.6M | -$906.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.08B | $837.0M | $478.0M |
| Capital Expenditures (CapEx) | $148.0M | $128.0M | $202.7M |
| Free Cash Flow (FCF) | $931.0M | $709.0M | $275.3M |
| FCF Margin % | 21.4% | 16.2% | 6.1% |
| Return on Invested Capital (ROIC %) | 18.0% | -20.9% | -5.8% |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | $1.55B | $1.47B | $5.64B |
| Total Stockholders' Equity | $2.72B | $2.37B | $11.56B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ILMN.